indomethacin has been researched along with Liver Diseases in 23 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hemodynamically significant patent ductus arteriosus (hsPDA) in very low birth weight (VLBW) infants is routinely treated in many countries with oral ibuprofen." | 8.02 | Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus. ( Guo, H; Huang, Y; Lin, HC; Liu, H; Peng, H; Shen, X; Yao, S; Zhou, M; Zhou, P, 2021) |
| " The cytoprotective effect of central TRH on CCl(4)-induced acute hepatocellular necrosis was abolished by hepatic branch vagotomy, atropine, indomethacin and N(G)-nitro-L-arginine methyl ester, but not by 6-hydroxydopamine." | 7.72 | Protective effect of central thyrotropin-releasing hormone on carbon tetrachloride-induced acute hepatocellular necrosis in rats. ( Makino, I; Nakamura, K; Sato, Y; Terano, A; Yoneda, M, 2003) |
| "To elucidate the effect of arachidonic acid metabolite inhibitors on liver injury in endotoxin shock with special reference to the role of polymorphonuclear leukocytes (PMNs), we pretreated rats with three kinds of arachidonic acid metabolite inhibitors (hydrocortisone, Hy; AA-861, AA; indomethacin, In) in our rat model of endotoxin shock." | 7.69 | [The effect of arachidonic acid metabolite inhibitors on liver injury in endotoxin shock, with special reference to the role of polymorphonuclear leukocytes (PMNs)]. ( Furukawa, K; Kobayashi, T; Onda, M, 1994) |
| "We evaluated the effect of ursodeoxycholic acid on the defective natural killer activity in primary biliary cirrhosis." | 7.69 | Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. ( Moriwaki, H; Muto, Y; Nishigaki, Y; Ohnishi, H, 1996) |
| "Hemodynamically significant patent ductus arteriosus (hsPDA) in very low birth weight (VLBW) infants is routinely treated in many countries with oral ibuprofen." | 4.02 | Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus. ( Guo, H; Huang, Y; Lin, HC; Liu, H; Peng, H; Shen, X; Yao, S; Zhou, M; Zhou, P, 2021) |
| " The cytoprotective effect of central TRH on CCl(4)-induced acute hepatocellular necrosis was abolished by hepatic branch vagotomy, atropine, indomethacin and N(G)-nitro-L-arginine methyl ester, but not by 6-hydroxydopamine." | 3.72 | Protective effect of central thyrotropin-releasing hormone on carbon tetrachloride-induced acute hepatocellular necrosis in rats. ( Makino, I; Nakamura, K; Sato, Y; Terano, A; Yoneda, M, 2003) |
| "To elucidate the effect of arachidonic acid metabolite inhibitors on liver injury in endotoxin shock with special reference to the role of polymorphonuclear leukocytes (PMNs), we pretreated rats with three kinds of arachidonic acid metabolite inhibitors (hydrocortisone, Hy; AA-861, AA; indomethacin, In) in our rat model of endotoxin shock." | 3.69 | [The effect of arachidonic acid metabolite inhibitors on liver injury in endotoxin shock, with special reference to the role of polymorphonuclear leukocytes (PMNs)]. ( Furukawa, K; Kobayashi, T; Onda, M, 1994) |
| "We evaluated the effect of ursodeoxycholic acid on the defective natural killer activity in primary biliary cirrhosis." | 3.69 | Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. ( Moriwaki, H; Muto, Y; Nishigaki, Y; Ohnishi, H, 1996) |
| "This study examines the effect of a purified leukocyte-derived endogenous mediator (LEM) on protein metabolism during liver dysfunction and after sham surgery and the role of a nonsteroidal, antiinflammatory drug (indomethacin sodium trihydrate) in modifying this response." | 3.67 | Leukocyte endogenous mediator fails to alter protein dynamics in a model of liver dysfunction. ( Bistrian, BR; Blackburn, GL; Dinarello, CA; Drabik, M; Flores, EA; Gauldie, J, 1989) |
| " The method was applied to patients with liver diseases and rheumatoid arthritis with and without treatment with antiinflammatory drugs and to rats after administration of indomethacin or carbon tetrachloride." | 3.66 | An improved method of determination of SH group concentration and reactivity in plasma of patients with various clinical disorders and in rats after administration of indomethacin or carbon tetrachloride. ( di Simplicio, P, 1983) |
| "Pretreatment with indomethacin completely reversed both of the therapeutic effects of dalteparin, whereas pretreatment with NS-398, a selective inhibitor of cyclooxygenase-2, did not." | 1.33 | Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats. ( Harada, N; Okajima, K; Uchiba, M, 2006) |
| "The hepatotoxicity of acetaminophen (APAP) overdose depends on metabolic activation to a toxic reactive metabolite via hepatic mixed function oxidase." | 1.28 | Acetaminophen hepatotoxicity: is there a role for prostaglandin synthesis? ( Ben-Zvi, Z; Danon, A; Katz, S; Weissman-Teitellman, B, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (39.13) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 2 (8.70) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, X | 1 |
| Huang, Y | 1 |
| Guo, H | 1 |
| Peng, H | 1 |
| Yao, S | 1 |
| Zhou, M | 1 |
| Liu, H | 1 |
| Lin, HC | 1 |
| Zhou, P | 1 |
| Rasooli, A | 1 |
| Fatemi, F | 1 |
| Hajihosseini, R | 1 |
| Vaziri, A | 1 |
| Akbarzadeh, K | 1 |
| Mohammadi Malayeri, MR | 1 |
| Dini, S | 1 |
| Foroutanrad, M | 1 |
| Abdel-Gaber, SA | 1 |
| Ibrahim, MA | 1 |
| Amin, EF | 1 |
| Ibrahim, SA | 1 |
| Mohammed, RK | 1 |
| Abdelrahman, AM | 1 |
| Sato, Y | 1 |
| Yoneda, M | 2 |
| Nakamura, K | 2 |
| Makino, I | 2 |
| Terano, A | 1 |
| Harada, N | 1 |
| Okajima, K | 1 |
| Uchiba, M | 1 |
| Rudnick, DA | 1 |
| Shikapwashya, O | 1 |
| Blomenkamp, K | 1 |
| Teckman, JH | 1 |
| di Simplicio, P | 1 |
| Kobayashi, T | 1 |
| Furukawa, K | 1 |
| Onda, M | 1 |
| Barriault, C | 1 |
| Audet, M | 1 |
| Yousef, IM | 1 |
| Tuchweber, B | 1 |
| Nishigaki, Y | 1 |
| Ohnishi, H | 1 |
| Moriwaki, H | 1 |
| Muto, Y | 1 |
| Manoukian, AV | 1 |
| Carson, JL | 1 |
| Ito, T | 1 |
| Takamoto, S | 1 |
| Nakade, Y | 1 |
| Okamoto, S | 1 |
| Okada, M | 1 |
| Yokohama, S | 1 |
| Aso, K | 1 |
| Horton, R | 1 |
| Zipser, R | 1 |
| Elliott, DE | 1 |
| Ragheb, S | 1 |
| Wellhausen, SR | 1 |
| Boros, DL | 1 |
| Müller, C | 1 |
| Zielinski, CC | 1 |
| Ben-Zvi, Z | 1 |
| Weissman-Teitellman, B | 1 |
| Katz, S | 1 |
| Danon, A | 1 |
| Flores, EA | 1 |
| Drabik, M | 1 |
| Gauldie, J | 1 |
| Blackburn, GL | 1 |
| Dinarello, CA | 1 |
| Bistrian, BR | 1 |
| Koyama, Y | 1 |
| Imoto, M | 1 |
| Tanaka, M | 1 |
| Fukuda, Y | 1 |
| Satake, T | 1 |
| Ozawa, T | 1 |
| Tajima, S | 1 |
| Nishimura, N | 1 |
| Ito, K | 1 |
| Kakumu, S | 1 |
| Tahara, H | 1 |
| Fuji, A | 1 |
| Yoshioka, K | 1 |
| Seissiger, L | 1 |
| Dell, HD | 1 |
| Uemura, M | 1 |
| Tsujii, T | 1 |
| Fukui, H | 1 |
| Kita, K | 1 |
| Takaya, A | 1 |
| Tsukamoto, N | 1 |
| Nakayama, M | 1 |
| Matsumoto, M | 1 |
| Tamura, M | 1 |
| Kawasaki, H | 1 |
| Murawaki, Y | 1 |
| Hirayama, C | 1 |
1 review available for indomethacin and Liver Diseases
| Article | Year |
|---|---|
Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chemical and Drug Induced Liver Injur | 1996 |
22 other studies available for indomethacin and Liver Diseases
| Article | Year |
|---|---|
Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
Topics: Birth Weight; Cholestasis; Ductus Arteriosus, Patent; Emulsions; Humans; Ibuprofen; Indomethacin; In | 2021 |
Synergistic effects of deuterium depleted water and Mentha longifolia L. essential oils on sepsis-induced liver injuries through regulation of cyclooxygenase-2.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cyclooxygenase 2; Deuterium; Disease Models, Animal | 2019 |
Effect of selective versus non-selective cyclooxygenase inhibitors on ischemia-reperfusion-induced hepatic injury in rats.
Topics: Alanine Transaminase; Animals; Caspase 3; Celecoxib; Cyclooxygenase 2 Inhibitors; Gene Expression Re | 2015 |
Protective effect of central thyrotropin-releasing hormone on carbon tetrachloride-induced acute hepatocellular necrosis in rats.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atropine; Carbon Tetrachloride; Che | 2003 |
Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion-induced liver injury in rats.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticoagulants; Calcium; Cyclooxygenase 2 Inhibitors; Daltepa | 2006 |
Indomethacin increases liver damage in a murine model of liver injury from alpha-1-antitrypsin deficiency.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Animals; Anti-Inflammatory Agents, Non-Steroida | 2006 |
An improved method of determination of SH group concentration and reactivity in plasma of patients with various clinical disorders and in rats after administration of indomethacin or carbon tetrachloride.
Topics: Animals; Arthritis, Rheumatoid; Carbon Tetrachloride; Humans; Indomethacin; Liver Diseases; Male; Ra | 1983 |
[The effect of arachidonic acid metabolite inhibitors on liver injury in endotoxin shock, with special reference to the role of polymorphonuclear leukocytes (PMNs)].
Topics: Animals; Arachidonic Acid; Benzoquinones; Hydrocortisone; Indomethacin; Liver Diseases; Male; Neutro | 1994 |
Protection by indomethacin against the lethality and hepatotoxicity of phalloidin in mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Aspirin; Chemical and Drug Induced Liver | 1994 |
Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis.
Topics: Adult; Aged; Cells, Cultured; Chenodeoxycholic Acid; Cholic Acid; Cholic Acids; Chronic Disease; Deo | 1996 |
Antithrombin III prevents concanavalin A-induced liver injury through inhibition of macrophage inflammatory protein-2 release and production of prostacyclin in mice.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antit | 2002 |
Prostaglandins: renin release and renal function.
Topics: Animals; Bartter Syndrome; Dogs; Homeostasis; Humans; Indomethacin; Ischemia; Kallikreins; Kidney; K | 1978 |
Interactions between adherent mononuclear cells and lymphocytes from granulomas of mice with schistosomiasis mansoni.
Topics: Animals; Antigens, Helminth; Concanavalin A; Granuloma; Immune Tolerance; Indomethacin; Interferon T | 1990 |
Impaired lipopolysaccharide-inducible tumor necrosis factor production in vitro by peripheral blood monocytes of patients with viral hepatitis.
Topics: Acute Disease; Adult; Aged; Chronic Disease; Female; Hepatitis, Viral, Human; Humans; Indomethacin; | 1990 |
Acetaminophen hepatotoxicity: is there a role for prostaglandin synthesis?
Topics: Acetaminophen; Animals; Aspirin; Chemical and Drug Induced Liver Injury; Glutathione; Hexobarbital; | 1990 |
Leukocyte endogenous mediator fails to alter protein dynamics in a model of liver dysfunction.
Topics: Acute-Phase Proteins; Amino Acids; Animals; Body Weight; Humans; Indomethacin; Interleukin-1; Liver | 1989 |
Changes in endogenous prostaglandin levels during D-galactosamine-induced liver injury.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromatography, High Pressure Liquid; Galactosamine | 1989 |
Suppression of delayed-type hypersensitivity mediated by macrophage-like cells in mice with experimental liver injury.
Topics: 1-Naphthylisothiocyanate; Animals; Carbon Tetrachloride; Catechin; Chemical and Drug Induced Liver I | 1985 |
Interleukin 1 alpha production by peripheral blood monocytes from patients with chronic liver disease and effect of sera on interleukin 1 alpha production.
Topics: Carrier State; Hepatitis B; Hepatitis, Chronic; Humans; In Vitro Techniques; Indomethacin; Interfero | 1988 |
[Acemetacin in patients with rheumatic disease with concomitant liver diseases. Pharmacokinetics, effectiveness and tolerance].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Inju | 1987 |
Urinary prostaglandins and renal function in chronic liver diseases.
Topics: Adult; Dinoprost; Dinoprostone; Female; Hemodynamics; Hepatitis; Hepatitis, Chronic; Humans; Indomet | 1986 |
Urinary kallikrein excretion in chronic liver disease and effect of indomethacin.
Topics: Aldosterone; Ascites; Bilirubin; Cholinesterases; Chronic Disease; Depression, Chemical; Humans; Ind | 1986 |